Výsledky vyhledávání - "Vince R. Torti"

Regulatory Experience Assessing the Carcinogenic Potential of a Monoclonal Antibody Inhibiting PCSK9, Bococizumab, Including a 2-Year Carcinogenicity Study in Rats

Autor: Bernard S. Buetow, Gregg D Cappon, Laura M. Aschenbrenner, Lawrence Updyke, Vince R. Torti, Mark Evans, Shana R. Dalton, Steven Bailey, Christopher J. Bowman

Publikováno v: International Journal of Toxicology. 41:389-401

Bococizumab is an anti-PCSK9 monoclonal antibody that was intended for the treatment of hypercholesterolemia. After reviewing the 6-month rat toxicity study data, in which there was a low spontaneous tumor incidence, unrelated to bococizumab administ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac7d16867d57951ce3092b8f8d26e92f
https://doi.org/10.1177/10915818221106397

Zobrazit plný text záznamu

Supplementary Figure 3 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901

Autor: Shubha Bagrodia, Leigh Ann Burns-Naas, Cynthia L. Palmer, Shinji Yamazaki, Tod Smeal, Lisa D. Marroquin, Gabriel Troche, Winston Evering, Annette John-Baptiste, Wenyue Hu, Donald Wojciechowicz, Vince R. Torti

PDF file, 141K, Photographs of canine muzzles showing skin flushing following PF-04880594 treatment.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c61562c2ac8f9673fec0772416b1013c
https://doi.org/10.1158/1535-7163.22497447

Zobrazit plný text záznamu

Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Table S2 shows a selectivity screen of PF-06840003 in in vitro pharmacological assays.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47698983ea67ec47db744f5010daf12a
https://doi.org/10.1158/1535-7163.22505134

Zobrazit plný text záznamu

Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Supplementary Methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f74526ae85eebdbe19c754931a606d3
https://doi.org/10.1158/1535-7163.22505140

Zobrazit plný text záznamu

Supplementary Figure 2 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901

PDF file, 75K, Body weight changes in nude mice administered RAF inhibitor (PF-04880594) are maintained in mice co-treated with MEK inhibitor (PD-0325901).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db70ae0a991103300fbe4c5905e2f65b
https://doi.org/10.1158/1535-7163.22497450

Zobrazit plný text záznamu

Data from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901

Clinical trials of selective RAF inhibitors in patients with melanoma tumors harboring activated BRAFV600E have produced very promising results, and a RAF inhibitor has been approved for treatment of advanced melanoma. However, about a third of patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42a4d07dbcb6946cf564cc5a49bca70c
https://doi.org/10.1158/1535-7163.c.6535623

Zobrazit plný text záznamu

Supplementary Figure 1 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901

PDF file, 39K, Relationship between oral doses and average plasma concentrations of PD-0325901 in athymic nu/nu mice.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::556345971e072ef862c9dc4beaaaf8d6
https://doi.org/10.1158/1535-7163.22497453.v1

Zobrazit plný text záznamu

Supplementary Figure Legend from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901

PDF file, 66K.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::506d7abfc15055ce5c5f19c73f418059
https://doi.org/10.1158/1535-7163.22497444.v1

Zobrazit plný text záznamu

Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Tumors use indoleamine 2,3-dioxygenase-1 (IDO1) as a major mechanism to induce an immunosuppressive microenvironment. IDO1 expression is upregulated in many cancers and considered to be a resistance mechanism to immune checkpoint therapies. IDO1 is i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b26f8def31d8e1dfcb01fcbd392ab72
https://doi.org/10.1158/1535-7163.c.6537964.v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání